In November 1997 a Task Force meeting was held in Milan on behalf of the European School of Oncology, during which various aspects of the role of dosage and timing of chemotherapy in solid tumours and lymphomas were discussed by a panel of experts. The present volume is concerned with some of the major topics in the fascinating and still only partially understood and developed field of medical oncology and haematology. Uncertainties and doubts continue to exist despite nearly twenty years of investigation into the subject ...
Read More
In November 1997 a Task Force meeting was held in Milan on behalf of the European School of Oncology, during which various aspects of the role of dosage and timing of chemotherapy in solid tumours and lymphomas were discussed by a panel of experts. The present volume is concerned with some of the major topics in the fascinating and still only partially understood and developed field of medical oncology and haematology. Uncertainties and doubts continue to exist despite nearly twenty years of investigation into the subject of dosage and timing of drug delivery. In the last few years, thousands of patients in Europe as well as the United States have received high-dose chemotherapy supported by haematopoietic rescue, although conflicting data still prevail in this area. The tendency towards the administration of higher doses might originate from the lack of breakthroughs in cancer treatment in the last decade, as well as from the revolutionary introduction into clinical practice of haematopoietic progenitor cells, and from phase II (many) and phase III (few) studies. Nevertheless, high-dose chemotherapy is not the only way to deliver "more". This book will inform the reader about what has been achieved, the state of current research and expected directions in research in the near future, as far as dosage and timing are concerned. It is not intended to be an apology for high-dose treatment but rather a serious and critical overview of knowledge.
Read Less